Supplementary Materials: A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score

Charlotte Maulat, Cindy Canivet, Célia Touraine, Sophie Gourgou, Bertrand Napoleon, Laurent Palazzo, Nicolas Flori, Guillaume Piessen, Pierre Guibert, Stéphanie Truant, Eric Assenat, Louis Buscail, Barbara Bournet and Fabrice Muscari

Table S1. Clinico-radiological and biological data collected.

Socio-demographic data		
Gender	**Educational level**	**Occupation**
Male	No diploma	Farmer
Female	General Certificate of Education	Artisan, storekeeper
Age	Vocational diploma	Executive, higher education profession
	Vocational training certificate	Intermediate level occupation
	Baccalaureate (SAT)	Employee
	Baccalaureate (SAT) +2	Manual worker
	Educational certificate	Retired
	Other	No professional activity
		Other
Medical history		
Smoking history	**Alcohol consumption**	**Family history of cancer**
Non-smoker	Non consumer	Yes
Former smoker	Former consumer	No
Current smoker	Current consumer	
Other pancreatic diseases	**History of diabetes**	
Yes	Yes	
No	No	
Symptoms on diagnosis		
Abdominal pain	**Jaundice**	**Chronic pancreatitis**
Yes	Yes	Yes
No	No	No
Random	**Weight loss**	**Recent diabetes**
Yes	Yes	Yes
No	No	No
Anorexia	**Acute pancreatitis**	*Gastrointestinal hemorrhage*
Yes	Yes	Yes
No	No	No
Biological anomaly	**Upper gastrointestinal obstruction**	**Arterial or venous thrombosis**
Yes	Yes	Yes
No	No	No
Ascites	**Transit disorders**	**Cholestatic syndrome**
Yes	Yes	Yes
No	No	No
Cholecystitis	**Fever**	**WHO performance status**
Yes	Yes	0
No	No	1
Usual BMI	**Current weight**	2
Current BMI	**Usual weight**	3
Biliary drainage		
Biliary drainage	**Percutaneous drainage**	**Endoscopic drain**

Yes	Yes	Metallic
No	No	Plastic
ERCP	**Radiological drain**	Drain
Yes	Metallic	
No	Plastic	
	Drain	
Description and characteristics of the pancreatic disease and the tumor (CT Scan or Endoscopic ultrasound)		
Location of the tumor	**Maximal tumor size (mm)**	**Type of initial imaging**
Head	**Conclusion of the paraclinical examinations**	Chest CT scan
Isthmus	Resectable	Abdominal CT scan
Body	Potentially resectable	Endoscopic ultrasound
Tail	Locally advanced	**IPMN**
Multiple	Metastatic	Yes
		No
Biological analysis on diagnosis		
Hemoglobin (g/dl)	INR	Gamma-GT (IU/l)
Leucocytes (G/l)	Albumin (g/l)	Alkaline Phosphatase (IU/l)
Neutrophils (G/l)	AST (IU/l)	Total bilirubin (μmol/l)
Platelets (G/l)	ALT (IU/l)	Creatinine (μmol/l)
CA 19-9 (IU/ml)	CEA (ng/ml)	
Anatomopathological analysis		
Puncture site	**Immunocytochemistry**	**Immunohistochemistry**
Primary tumor	Yes	Yes
Liver	No	No
Node		
Another metastasis		
Multiple		
Treatment		
Resectable group treatment (surgery and after surgery)		
Type of surgery	**TNM staging**	**Clavien-Dindo classification**
Whipple procedure	Ia	Grade I
Left pancreatectomy without splenic preservation	Ib	Grade II
Left pancreatectomy with splenic preservation	IIa	Grade IIIa
Pancreatic fistula	IIb	Grade IIIb
Yes	III	Grade IVa
No	IV	Grade IVb
		Grade V
Locally advanced group treatment (type of chemotherapy)		
Metastatic group treatment (type of chemotherapy)		
Delays (days)		
Between symptoms and first radiological exam	Between biopsy and surgery	Between biopsy and first line chemotherapy
Between symptoms and anatomopathological analysis	Between symptoms and first line chemotherapy	Between MTM inclusion and surgery
Between symptoms and surgery	Between MTM inclusion and first line chemotherapy	Between first line of chemotherapy and tumor progress

BMI: Body Mass Index, IPMN: intraductal papillary mucinous neoplasm, ERCP: Endoscopic Retrograde Cholangiopancreatography, CT scan: Computed Tomography scan, IPMN: intraductal papillary mucinous neoplasm, MTM: Multidisciplinary Team Meeting, WHO: World Health Organization, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, CEA: Carcinoembryonic antigen, Ca 19-9: Carbohydrate antigen 19-9.